Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Feb 28, 2019 9:42am
93 Views
Post# 29422278

RE:RE:Just received from Sarah- BOM Queries

RE:RE:Just received from Sarah- BOM Queries"So presumably this single endpoint can be determined in a reasonably short period of time by a medical practitioner, pre-adjudication."

G1945V, that makes sense. IR recently told us "We have not publicly disclosed the breakdown between adjudicated MACE events vs unadjudicated." And IR replied to RVXoldtimer that MACE events are being adjudicated on an ongoing basis. So some of these 220+ narrow 3-point MACE events are adjudicated, some are not yet adjudicated. But as you pointed out, they must have a pretty solid idea pre-adjudication as to whether it is indeed a narrow 3-point MACE. Of course, during the adjudication process, a suspected event may either be confirmed and moved into the officially adjudicated category, or alternatively removed fromt the count if the suspected event is found to not actually be a narrow 3-point MACE during adjudication. The trigger end of dosing is likely 250 adjudicated 3-point MACE events. Since the event totals at corporate updates have been likely a combo of adjudicated and unadjudicated, we need to wait until 250 adjudicated before trial completion/end of dosing, which likely required material disclosure. I posted a potential order of expected events last night in this post.All in my opinion. DYODD.

BearDownAZ
Bullboard Posts